The combination of the off-the-shelf cancer immune primer ilixadencel and sunitinib (Sutent) elicited a 11% complete response (CR) rate in patients with metastatic renal cell carcinoma (RCC), according to topline findings from the phase II MERECA trial (NCT02432846).
“Our main objective for MERECA was to explore the therapeutic benefit of ilixadencel in combination with a standard treatment regimen. The surprising number of complete responses in advanced-stage cancer patients is particularly encouraging and highly supportive of our vision for ilixadencel as a backbone therapy in modern cancer treatment regimens,” Carlos de Sousa, CEO of Immunicum, stated in the press release. “We are eager to conduct the full analysis of the data and use that to refine and accelerate ilixadencel’s clinical development.”
Immunicum AB (publ) Announces Positive Phase II MERECA Topline Results Including Complete Tumor Responses in Metastatic Renal Cell Carcinoma Patients. Immunicum AB (publ). Published August 29, 2019. Accessed August 29, 2019. https://bit.ly/2zxwutL.
... to read the full story